At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Normalizing Platelet Reactivity After Treatment With Ticagrelor
In Brief
A Phase 4 clinical trial evaluating Ticagrelor loading dose, Aspirin loading dose, and 2 other interventions for Coronary Artery Disease. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Acute coronary syndrome (ACS) patients treated with antiplatelet drugs who require coronary artery bypass grafting (CABG) surgery have to wait 5-7 days for the effects of the drugs to wean off. This treatment-devoid period leaves the patient vulnerable, therefore any means to shorten this period could be useful. The present study aims to investigate the possibility of reversing the antiplatelet effects of ticagrelor with the help of fresh donor platelets. Fresh platelets will be added to blood samples of treated patients in varying concentrations at specific timepoints to determine the time and amount of fresh platelets needed to normalize platelet reactivity in the treated samples.
Study Details
Timeline
Interventions
Single loading dose of Ticagrelor 180 mg
Single loading dose of Aspirin 325 mg
Ticagrelor 90 mg twice daily x 7 days
Aspirin 81 mg once daily x 7 days